Continuing Evolution of Implantable Cardioverter/Defibrillators: Smaller Size, Longer Life, Improved Cost-Effectiveness

作者: Seah Nisam

DOI: 10.1007/978-94-011-5254-9_41

关键词:

摘要: In less than two decades since Michel Mirowski introduced the implantable cardioverter/defibrillator (ICD) into clinical practice, it has been acknowledged as most effective therapy for protecting patients against sudden arrhythmic death, due to ventricular tachycardia or fibrillation (VT/VF)1–3. Many factors have contributed elevating ICD from a treatment “of last resort” primary intervention such patients. Certainly, growing evidence that no antiarrhythmic drugs able improve survival played major role. However, without improvements in technology, resulting implantation procedures similar cardiac pacing, is unlikely would attained current high degree of acceptance — by physicians and The obvious aspects this technological evolution are size. transvenous implantation, device reliability longevity, ease-of-use. At same time, continued pressure on health expenditures brought great focus proving cost-effectiveness, so authorities grant reimbursement sophisticated technology. questions which we will address chapter concern particular balance between cost-effectiveness rapid improvements.

参考文章(23)
Philip R. Reid, Morton M. Mower, Levi Watkins, Vincent L. Gott, James F. Schauble, Alois Langer, M. S. Heilman, Steve A. Kolenik, Robert E. Fischell, Myron L. Weisfeldt, M. Mirowski, Termination of Malignant Ventricular Arrhythmias with an Implanted Automatic Defibrillator in Human Beings New England Journal of Medicine. ,vol. 303, pp. 322- 324 ,(1980) , 10.1056/NEJM198008073030607
Seah Nisam, Technology Update: The Modern Implantable Cardioverter Defibrillator Annals of Noninvasive Electrocardiology. ,vol. 2, pp. 69- 78 ,(1997) , 10.1111/J.1542-474X.1997.TB00311.X
John M. Herre, Mary Jane Sauve, Patricia Malone, Jerry C. Griffin, Ibrahim Helmy, Jonathan J. Langberg, Harold Goldberg, Melvin M. Scheinman, Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation Journal of the American College of Cardiology. ,vol. 13, pp. 442- 449 ,(1989) , 10.1016/0735-1097(89)90525-1
Richard N.W Hauer, Richard Derksen, Eric F.D Wever, Can Implantable Cardioverter-Defibrillator Therapy Reduce Healthcare Costs?* American Journal of Cardiology. ,vol. 78, pp. 134- 139 ,(1996) , 10.1016/S0002-9149(96)00516-4
STEPHEN J. HAHN, CURT C. LINDSTROM, DEAN L. DERFUS, Implantable cardioverter defibrillator lead technology: improved performance and lower defibrillation thresholds. Pacing and Clinical Electrophysiology. ,vol. 18, pp. 548- 559 ,(1995) , 10.1111/J.1540-8159.1995.TB02565.X
R. Valenti, J. Schlapfer, M. Fromer, A. Fischer, L. Kappenberger, Impact of the implantable cardioverter-defibrillator on rehospitalizations. European Heart Journal. ,vol. 17, pp. 1565- 1571 ,(1996) , 10.1093/OXFORDJOURNALS.EURHEARTJ.A014722
Steven L. Higgins, Helmut Klein, Seah Nisam, Which device should MADIT protocol patients receive American Journal of Cardiology. ,vol. 79, pp. 31- 35 ,(1997) , 10.1016/S0002-9149(97)00119-7
David Newman, Mary Jane Sauve, John Herre, Jonathan J. Langberg, Michael A. Lee, Christina Titus, Jay Franklin, Melvin M. Scheinman, Jerry C. Griffin, Survival after implantation of the cardioverter defibrillator. American Journal of Cardiology. ,vol. 69, pp. 899- 903 ,(1992) , 10.1016/0002-9149(92)90789-2